Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/treatment-of-anthracycline-resistant-breast-cancer-ErcxAkWoQ2
References (73)
-
M. O'brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D. Kieback, P. Tomczak, S. Ackland, F. Orlandi, L. Mellars, L. Alland, C. Tendler (2004)
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 15 3
-
D. Lombardi, M. Magri, D. Crivellari, S. Spazzapan, C. Paolello, M. Cicco, V. Lauro, C. Scuderi, A. Veronesi (2000)
Combination chemotherapy with navelbine and continuous infusion of 5-fluorouracil in metastatic, chemotherapy refractory breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 11 8
-
Dieras, M. Marty, N. Tubiana, L. Corette, F. Morvan, D. Serin, L. Mignot, M. Chazard, F. Garet, N. Onetto (1995)
Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer.Seminars in oncology, 22 4 Suppl 8
-
M. Zambetti, G. Mariani, R. Demicheli, P. Verderio, P. Potepan, F. Garbagnati (2000)
Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclines and paclitaxelBreast Cancer Research and Treatment, 62
-
P. Geels, E. Eisenhauer, A. Bezjak, B. Zee, A. Day (2000)
Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 12
-
Maureen Meade, W. Richardson (1997)
Selecting and Appraising Studies for a Systematic ReviewAnnals of Internal Medicine, 127
-
E. Perez, C. Vogel, D. Irwin, J. Kirshner, Ravi Patel (2001)
Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 22
-
G. Frasci, P. Comella, G. D'aiuto, R. Thomas, I. Capasso, M. Elmo, G. Botti, G. Cortino, L. Lapenta, V. Rosa, P. Vallone, A. Petrillo, G. Comella (2000)
Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).Annals of oncology : official journal of the European Society for Medical Oncology, 11 3
-
R. A'Hern, SR Ebbs, MB Baum (1988)
Does chemotherapy improve survival in advanced breast cancer? A statistical overview.British Journal of Cancer, 57
-
N. Kröger, W. Achterrath, S. Hegewisch-Becker, K. Mross, A. Zander (1999)
Current options in treatment of anthracycline-resistant breast cancer.Cancer treatment reviews, 25 5
-
Pauline Leung, I. Tannock, A. Oza, A. Puodziunas, G. Dranitsaris (1999)
Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 10
-
P. Ravdin, H. Burris, Gayle Cook, P. Eisenberg, M. Kane, William Bierman, J. Mortimer, Eric Genevois, R. Bellet (1995)
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 12
-
R. Valenza, V. Leonardi, V. Gebbia, B. Agostara (2000)
Gemcitabine and vinorelbine in pretreated advanced breast cancer: a pilot study.Annals of oncology : official journal of the European Society for Medical Oncology, 11 4
-
E. Rivera, L. Sutton, B. Colwell, M. Graham, D. Frye, M. Somerville, H. Conklin, C. McGuirt, J. Levin, G. Hortobagyi (2002)
Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 4
-
G. Frasci, P. Cornelia, G. D’Aiuto (2000)
Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose- finding studyAnn Oncol, 11
-
M. Spielmann, A. Llombart, L. Zelek, R. Sverdlin, O. Rixe, A. Cesne (1999)
Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 10 12
-
T. Brodowicz, R. Moslinger, V. Herscovic (1998)
Second and third-line treatment of metastatic breast cancer with gemcitabine [abstract]Eur J Cancer, 34
-
D. Belpomme, S. Gauthier, E. Pujade-Lauraine, T. Facchini, M. Goudier, I. Krakowski, G. Netter-Pinon, M. Frénay, C. Gousset, F. Marie, M. Benmiloud, F. Sturtz (2000)
Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma.Annals of oncology : official journal of the European Society for Medical Oncology, 11 11
-
R. A'Hern, I. Smith, S. Ebbs (1993)
Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.British Journal of Cancer, 67
-
Y. Nieto, M. Martin, J.L. Alonso (1998)
Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicin BreastCancer Res Treat, 50
-
J. Blum, V. Diéras, P. Russo, J. Horton, O. Rutman, A. Buzdar, B. Osterwalder (2001)
Multicenter, Phase II study of capecitabine in taxane‐pretreated metastatic breast carcinoma patientsCancer, 92
-
H.J. Stemmler, K. Gutschow, H. Sommer (2001)
Weekly docetaxel in patients with metastatic breast cancerAnn Oncol, 12
-
G. Cocconi, A. Mambrini, M. Quarta, G. Vasini, M. Bella, F. Ferrozzi, Myriam Beretta (2000)
Vinorelbine combined with paclitaxel infused over 96 hours (VI‐TA‐96) for patients with metastatic breast carcinomaCancer, 88
-
Raquel Andrés, J. Mayordomo, Dolores Isla, J. Martí, Pilar Escudero, E. Filipovich, A. Sáenz, I. Álvarez, E. Polo, A. Trés (2002)
Responses to docetaxel plus vinorelbine in metastatic breast cancer patients failing high-dose chemotherapyBritish Journal of Cancer, 86
-
J. O’Shaughnessy, D. Miles, S. Vukelja, V. Moiseyenko, J. Ayoub, G. Cervantes, P. Fumoleau, Stephen Jones, W. Lui, L. Mauriac, C. Twelves, G. Hazel, S. Verma, R. Leonard (2002)
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 12
-
T. Skovsgaard, N. Davidson, M. Piccart, D. Richel, J. Bonneterre, D. Cirkel, C. Barton (2001)
A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 12 9
-
M. Clarke, R. Collins, C. Davies, J. Godwin, R. Gray, R. Peto (1998)
Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 352
-
M. Vassilomanolakis, G. Koumakis, V. Barbounis, M. Demiri, H. Pateras, A. Efremidis (2000)
Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines.Annals of oncology : official journal of the European Society for Medical Oncology, 11 9
-
M. Martín, A. Lluch, A. Casado, I. Carbonero, L. Paz, C. Esteban, A. Insa, R. Alfonso, J. Garcia-conde, E. Díaz-Rubio (2000)
Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure.Annals of oncology : official journal of the European Society for Medical Oncology, 11 1
-
C. Smorenburg, M. Bontenbal, C. Seynaeve, C. Zuylen, G. Heus, J. Verweij, R. Wit (2001)
Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxaneBreast Cancer Research and Treatment, 66
-
J. Alexandre, P. Bleuzen, J. Bonneterre, William Sutherland, J. Misset, J. Guastalla, Patrice Viens, Sandrine Faivre, A. Chahine, M. Spielman, A. Bensmaïne, Michel Marty, M. Mahjoubi, Esteban Cvitkovic (2000)
Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 3
-
M. Spielmann, S. Kalla, A. Llombart-Cussac (1997)
Activity of gemcitabine in metastatic breast cancer patients previously treated with an anthracycline- containing regimens [abstract]Eur J Cancer, 33
-
M. Cobleigh, C. Vogel, D. Tripathy, N. Robert, S. Scholl, L. Fehrenbacher, J. Wolter, V. Paton, S. Shak, G. Lieberman, D. Slamon (1999)
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 9
-
T. Brodowicz, R. Möslinger, V. Herscovici, I. Vaclavik, C. Wiltschke, E. Kubista, C. Zielinski (1998)
Second- and third-line treament of metastatic breast cancer with gemcitabineEuropean Journal of Cancer, 34
-
J. Bonneterre, H. Roché, P. Kerbrat, A. Brémond, P. Fumoleau, M. Namer, M. Goudier, S. Schraub, P. Fargeot, I. Chapelle-Marcillac (2005)
Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 12
-
A. Venturino, D. Comandini, C. Simoni, L. Merlini, C. Naso, R. Palumbo, V. Fusco, G. Porcile, P. Pronzato, R. Rosso, L. Repetto (2000)
Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorinBreast Cancer Research and Treatment, 60
-
H. Stemmler, K. Gutschow, H. Sommer, M. Malekmohammadi, C. Kentenich, R. Forstpointner, S. Geuenich, J. Bischoff, W. Hiddemann, V. Heinemann (2001)
Weekly docetaxel (Taxotere) in patients with metastatic breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 12 10
-
M. Levine, V. Bramwell, K. Pritchard, B. Norris, L. Shepherd, H. Abu‐Zahra, B. Findlay, D. Warr, D. Bowman, J. Myles, A. Arnold, T. Vandenberg, R. Mackenzie, J. Robert, J. Ottaway, M. Burnell, C. Williams, D. Tu (1998)
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 8
-
P. Ravdin, J. Erban, B. Overmoyer (2003)
Phase III comparison of taxotere and paclitaxel in patients with metstatic breast cancer (TAX 311)Eur J Cancer, 5
-
H. Salman, Katherine Tanaka, J. Sparano (2002)
Phase I/II trial of gemcitabine plus cyclophosphamide in patients with metastatic breast carcinoma previously treated with taxanes.Clinical breast cancer, 2 4
-
Fatima Cardoso, A. Leo, Caroline Lohrisch, Chantal Bernard, Fábio Ferreira, Martine Piccart (2002)
Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?Annals of oncology : official journal of the European Society for Medical Oncology, 13 2
-
(2001)
Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trialJ Clin Oncol, 19
-
M. Villalona-Calero, M. Villalona-Calero, Joanne Blum, S. Jones, S. Diab, R. Elledge, P. Khoury, D. Hoff, M. Kraynak, J. Moczygemba, P. Kromelis, Tom Griffin, E. Rowinsky, E. Rowinsky (2001)
A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.Annals of oncology : official journal of the European Society for Medical Oncology, 12 5
-
G. Ellis, J. Gralow, H. Pierce, M. Williams, R. Livingston (1999)
Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicin-treated patients.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 5
-
H. Lamb, L. Wiseman (1998)
Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.PharmacoEconomics, 14 4
-
J. Bonneterre, H. Roche, A. Monnier (1997)
Taxotere versus 5-fluorouracil plus Navelbine as second-line chemotherapy in patients with metastatic breast cancer [abstract 564]Proc Am Soc Clin Oncol, 16
-
N. Ibrahim, Z. Rahman, V. Valero, J. Willey, R. Theriault, A. Buzdar, J. Murray, R. Bast, G. Hortobagyi (1999)
Phase II study of vinorelbine administered by 96‐hour infusion in patients with advanced breast carcinomaCancer, 86
-
J. Martí, P. Bueso, J. Mayordomo, M. Isla, A. Sáenz, P. Escudero, L. Murillo, E. Filipovich, R. Andrés, A. Trés (2001)
Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines.Annals of oncology : official journal of the European Society for Medical Oncology, 12 8
-
D. Talbot, V. Moiseyenko, S. Belle, S. O’Reilly, E. Conejo, S. Ackland, P. Eisenberg, D. Melnychuk, T. Pieńkowski, H. Burger, S. Laws, B. Osterwalder (2002)
Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclinesBritish Journal of Cancer, 86
-
C. Garufi, C. Nisticó, S. Brienza, A. Vaccaro, A. D'Ottavio, A. Zappalà, A. Aschelter, E. Terzoli (2001)
Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study.Annals of oncology : official journal of the European Society for Medical Oncology, 12 2
-
J. Vermorken, W. Huinink, I. Mandjes, T. Postma, M. Huizing, J. Heimans, J. Beijnen, F. Bierhorst, H. Pinedo, B. Winograd (1995)
High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.Seminars in oncology, 22 4 Suppl 8
-
D. Mavroudis, N. Malamos, A. Alexopoulos (1999)
Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trialAnn Oncol, 10
-
M. Zambetti, G. Mariani, R. Demicheli (2000)
Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclinesBreast Cancer Res Treat, 62
-
J. Nabholtz, H. Senn, W. Bezwoda, D. Melnychuk, L. Deschênes, J. Douma, T. Vandenberg, B. Rapoport, R. Rosso, V. Trillet‐Lenoir, J. Drbal, A. Molino, J. Nortier, D. Richel, T. Nagykálnai, P. Siedlecki, N. Wilking, J. Genot, P. Hupperets, F. Pannuti, D. Skarlos, E. Tomiak, M. Murawsky, M. Alakl, A. Riva, M. Aapro (1999)
Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing ChemotherapyJournal of Clinical Oncology, 17
-
G. Mariani, P. Tagliabue, P. Zucchinelli, C. Brambilla, R. Demicheli, E. Villa, A. Marchiano, P. Valagussa, G. Bonadonna, L. Gianni (2001)
Phase I/II study of gemcitabine in association with vinorelbine for metastatic breast cancerBreast Cancer Research and Treatment, 70
-
Y. Nieto, Miguel Martín, J. Alonso, A. Casado, F. Ayala, J. López-Martín, Á. Rodríguez-Lescure, E. Díaz-Rubio (1998)
Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicinBreast Cancer Research and Treatment, 50
-
J. Nabholtz, K. Gelmon, M. Bontenbal, M. Spielmann, G. Catimel, P. Conte, U. Klaassen, M. Namer, J. Bonneterre, P. Fumoleau, B. Winograd (1996)
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 6
-
J. Crown (2001)
The platinum agents: a role in breast cancer treatment?Seminars in oncology, 28 1 Suppl 3
-
D. Mavroudis, N. Malamos, A. Alexopoulos, C. Kourousis, S. Agelaki, E. Sarra, A. Potamianou, Ch. Kosmas, G. Rigatos, T. Giannakakis, K. Kalbakis, F. Apostolaki, J. Vlachonicolis, S. Kakolyris, G. Samonis, V. Georgoulias (1999)
Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.Annals of oncology : official journal of the European Society for Medical Oncology, 10 2
-
M.N. Levine, V.H. Bramwell, K.I. Pritchard (1998)
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancerJ Clin Oncol, 16
-
M. Ando, T. Watanabe, K. Nagata, M. Narabayashi, I. Adachi, N. Katsumata (2001)
Efficacy of docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 2
-
J. Sjöström, C. Blomqvist, H. Mouridsen, A. Płużańska, S. Ottosson-Lönn, N. Bengtsson, B. Østenstad, I. Mjaaland, M. Palm-Sjövall, E. Wist, V. Valvere, H. Anderson, J. Bergh (1999)
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.European journal of cancer, 35 8
-
R. Fossati, C. Confalonieri, V. Torri, E. Ghislandi, A. Penna, V. Pistotti, A. Tinazzi, A. Liberati (1998)
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 10
-
V. Valero, F. Holmes, R. Walters, R. Theriault, L. Esparza, G. Fraschini, G. Fonseca, R. Bellet, A. Buzdar, G. Hortobagyi (1995)
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 12
-
U. Klaassen, H. Wilke, A. Harstrick, C. Pari, D. Strumberg, K. Neumann, Wilfried Eberhardt, W. Achterrath, L. Lenaz, S. Seeber (1998)
Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second-line treatment of metastatic breast cancer: results of a phase II study.Annals of oncology : official journal of the European Society for Medical Oncology, 9 1
-
X. Pivot, Lina Asmar, A. Buzdar, Vicente Valero, G. Hortobagyi (2000)
A unified definition of clinical anthracycline resistance breast cancerBritish Journal of Cancer, 82
-
S. Jones, Eric Winer, C. Vogel, L. Laufman, L. Hutchins, M. O'Rourke, B. Lembersky, D. Budman, J. Bigley, J. Hohneker (1995)
Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 10
-
J. Abrams, D. Vena, J. Baltz, J. Adams, M. Montello, M. Christian, N. Onetto, S. Desmond-Hellmann, R. Canetta, M. Friedman (1995)
Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 8
-
R. Launois, J. Reboul-Marty, B. Henry (1996)
A cost-utility analysis of second-line chemotherapy in metastatic breast cancer: Docetaxel versus paclitaxel versus vinorelbinePharmacoecnomics, 10
-
C. Campisi, A. Fabi, P. Papaldo, S. Tomao, Bruno Massidda, A. Zappalà, M. Ionta, F. Cognetti (1998)
Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial.Annals of oncology : official journal of the European Society for Medical Oncology, 9 5
-
J. Hutton, R. Brown, M. Rorowitz (1996)
A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancerPharmacoeconomics, 9
-
A. Tortoriello, G. Facchini, F. Caponigro, M. Santangelo, G. Benassai, G. Persico, A. Citarella, M. Carola, N. Marzano, R. Iaffaioli (2004)
Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancerBreast Cancer Research and Treatment, 47
-
I. Ray-Coquard, P. Biron, T. Bachelot, J. Guastalla, G. Catimel, Y. Merrouche, J. Droz, F. Chauvin, J. Blay (1998)
Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline‐ and/or paclitaxel‐containing regimensCancer, 82
- Publisher
- Springer Journals
- Copyright
- Copyright © 2004 by Adis Data Information BV
- Subject
- Pharmacy; Pharmacy
- ISSN
- 1175-6357
- DOI
- 10.2165/00024669-200403030-00002
- Publisher site
- See Article on Publisher Site
Abstract
The anthracyclines are commonly used for the treatment of early stage and advanced stage breast cancer, but many patients develop resistance to therapy. The definition of anthracycline resistance varies considerably in the literature, but in most cases includes disease progression during or within 6–12 months after completion of anthracycline therapy. Some authors have distinguished true anthracycline resistance (defined as progression during anthracycline therapy) from anthracycline pretreatment (defined as progression after completion of therapy).
Journal
American Journal of Cancer – Springer Journals
Published: Aug 10, 2012